Promoted Content
Promoted Content

Find Drugs for Infections and Infectious Diseases in Phase II Clinical Development in FRANCE

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VLA15

            Therapeutic Area: Infections and Infectious Diseases Product Name: VLA15

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Pfizer Inc

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 02, 2020

            Details:

            Valneva plans to accelerate pediatric development of its Lyme vaccine candidate, VLA15, in collaboration with Pfizer Inc. (NYSE: PFE), with the planned initiation of study VLA15-221 in the first quarter of 2021, subject to regulatory approval.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Masitinib Mesylate,Isoquercitrin

            Therapeutic Area: Infections and Infectious Diseases Product Name: AB1010

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: European Investment Bank

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement November 30, 2020

            Details:

            This agreement will enable AB Science to fund the clinical development programme evaluating masitinib as a treatment for COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Masitinib Mesylate,Isoquercitrin

            Therapeutic Area: Infections and Infectious Diseases Product Name: AB1010

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 02, 2020

            Details:

            Starting from a library of 1,900 clinically used drugs, either approved for human use or in late stage clinical development, masitinib stood-out in its ability to completely inhibit activity of the SARS-CoV-2 main protease (3CLpro), thereby blocking viral replication.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Avdoralimab

            Therapeutic Area: Infections and Infectious Diseases Product Name: IPH5401

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 29, 2020

            Details:

            The study found that patients who progress towards severe COVID-19 disease, including those with severe pneumonia and acute respiratory distress syndrome (ARDS), exhibit an activation of the C5a/C5aR1 pathway.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Nangibotide

            Therapeutic Area: Infections and Infectious Diseases Product Name: LR12

            Highest Development Status: Phase II Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 23, 2020

            Details:

            Nangibotide is a TREM-1 pathway inhibitor with multiple potential indications, such as septic shock and myocardial infarction. TREM-1 is an immunomodulatory receptor found on innate immune cells, which increases and maintains inflammation.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Oxaquin

            Therapeutic Area: Infections and Infectious Diseases Product Name: DNV3837

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 15, 2020

            Details:

            DNV3837 targets the treatment of Clostridioides difficile gastrointestinal infections (CDI), a pathogen classified as urgent threat by the U.S. Centers for Disease Control and Prevention (CDC).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OVX836

            Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: European Innovation Council

            Deal Size: $34.0 million Upfront Cash: Undisclosed

            Deal Type: Funding July 08, 2020

            Details:

            The grant willsupport the completion of the Company’s Phase 2a immunogenicity clinical trial for OVX836, its lead universal flu vaccine candidate and the early discovery phase for its universal coronavirus vaccine program.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VLA15

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Pfizer Inc

            Deal Size: $308.0 million Upfront Cash: $130.0 million

            Deal Type: Agreement June 08, 2020

            Details:

            Valneva and Pfizer will work closely together throughout the development of VLA15. The agreement was signed at the end of April 2020 to develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical studies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VLA15

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Pfizer Inc

            Deal Size: $308.0 million Upfront Cash: $130.0 million

            Deal Type: Collaboration April 30, 2020

            Details:

            Valneva and Pfizer will work closely together to develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical studies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Avdoralimab

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 28, 2020

            Details:

            First patient was dosed in a randomized, double-blind Phase II clinical trial, evaluating the safety and efficacy of its anti-C5aR antibody, avdoralimab (IPH5401), in COVID-19 patients.